Senate Commerce/Science Subcommittee Chairman Ron Wyden (R-Ore.) no longer plans hearings or legislation to address the return to taxpayers from research funded by the National Institutes of Health. Wyden met Oct. 10 with reps from NIH, the pharmaceutical industry and research institutions. Wyden is understood to be satisfied by NIH's plan to begin implementation of a web-based database of approved drugs that use technology funded by NIH and to use standardized language to simplify reporting requirements by Jan. 1 (1"The Pink Sheet" Aug. 27, p. 3)
You may also be interested in...
The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials